2511.HK

HighTide Therapeutics, Inc. operates as an investment holding company focused on the entire lifecycle from discovery to commercialization of innovative, multi-faceted therapeutic solutions. These solutions are specifically engineered to tackle metabolic and digestive disorders where current treatments fall short. The company's flagship pharmaceutical candidate, HTD1801, functions as a gut-liver anti-inflammatory metabolic modulator. It is being developed to address a range of severe conditions, including metabolic dysfunction-associated steatohepatitis, type 2 diabetes mellitus, severe hypertriglyceridemia, primary sclerosing cholangitis, and primary biliary cholangitis. Furthermore, HighTide's development pipeline includes HTD4010, a polypeptide medication for alcoholic hepatitis; HTD1804, designed to combat obesity; HTD1805, a versatile small molecule drug targeting various metabolic ailments; and HTD2802, intended for the management of inflammatory bowel disease. Established in 2011, HighTide Therapeutics, Inc. maintains its headquarters in Shenzhen, China.